Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.

ABSTRACT:

Introduction

Tirzepatide, a dual GIP/GLP-1 receptor agonist, is highly effective in reducing body weight and improving glucometabolic outcomes. However, most clinical trials have overlooked the role of diet quality, leaving unclear whether lifestyle factors may modulate pharmacological benefits. The Mediterranean diet, assessed through the validated PREDIMED score, has proven effects on visceral adiposity and metabolic health and may act synergistically with novel incretin therapies.

Materials and methods

We enrolled 53 patients with overweight/obesity eligible for tirzepatide (BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with comorbidities). Participants were clinically assessed at baseline (T0) and after a median of 3 months (T1) of treatment (2.5 mg/week for 1 m

SUBMITTER: Paterno V 

PROVIDER: S-EPMC12846957 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature